Corcym provides advanced surgical heart valve solutions, addressing the growing global demand for durable and innovative cardiac surgery technologies
To company website
At a glance
Sector: Healthcare
Vertical: Medtech
Reference market: Cardiac surgery
Investment type: Carve-out
Acquisition: 2021
Head office: Italy
FTEs: ~800
Overview
- Formed in 2021 through the carve-out of LivaNova’s heart valve business (formerly Sorin)
- Offers a portfolio of 30+ devices, including flagship platforms—Perceval, Memo, and HAART—protected by 70+ patents
- Global reach across 100+ countries, with manufacturing in Italy and Canada
- Positive impact to society: delivers life-saving solutions for structural heart disease, a leading global health challenge
Positive impact to society
Delivers life-saving solutions for structural heart disease, a leading global health challenge
Investment rationale
- Operates in a growing market driven by aging populations, greater healthcare access, innovation, and rising incidence of cardiac diseases
- Strategic platform for shaping the future of cardiac surgery - from open procedures to minimally invasive and robotic approaches - offering more durable alternatives vs. transcatheter solutions
- Pursuing the ambition to be a leading player in robotic-enabled cardiac surgery
